Only half of psychiatric facilities offer MOUD: Study

Abstract

In “Availability of Medications for Opioid Use Disorder in U.S. Psychiatric Hospitals,” Shawn M. Cohen, M.D., and colleagues expose the inadequacy of methadone, buprenorphine and naltrexone in psychiatric hospitals. The study, published as a research letter in JAMA Network Open this month, consisted of a cross-sectional analysis of facility-level responses to the 2022 National Substance Use and Mental Health Services Survey. The study sample included all facilities in the U.S. that self-reported their facility type as a psychiatric hospital and reported their availability of medications for opioid use disorder (MOUD).